Healthcare company CrossBay Medical Inc reported on Thursday the receipt of marketing clearance to commercialise its Endometrial Tissue Sampler (ETS) using CrossGlide technology for use in endometrial biopsy procedures in Europe.

CrossGlide technology provides a novel way to obtain an office-based endometrial biopsy, a very common tissue-sampling procedure performed in women's health offices worldwide, the company said.

The ETS is the third product from the company using the frictionless CrossGlide technology to receive marketing authorisation. The product will be made available for use in endometrial biopsy procedures in the coming months.

Based on the company's CrossGlide technology, the ETS is designed to require no grasping or manipulation of the cervix to allow for easy, dependable access into the uterine cavity regardless of the complexity or variability of the patient's specific anatomy.

There are approximately four million endometrial biopsies performed per year in the EU and US for gynaecological indications and there are an additional two million endometrial biopsies performed globally for infertility reasons. CrossBay Medical will continue to develop and commercialise medical devices using CrossGlide across a wide array of gynaecological applications in the coming years.